Chelsea Counsel Company’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.3M | Sell |
9,374
-1,500
| -14% | -$535K | 1.47% | 19 |
|
|
2025
Q4 | $3.56M | Sell |
10,874
-75
| -0.7% | -$23.8K | 1.53% | 20 |
|
|
2025
Q3 | $3.09M | Sell |
10,949
-1,933
| -15% | -$561K | 1.37% | 21 |
|
|
2025
Q2 | $3.6M | Sell |
12,882
-135
| -1% | -$38.2K | 1.78% | 15 |
|
|
2025
Q1 | $4.06M | Hold |
13,017
| – | – | 2.2% | 12 |
|
|
2024
Q4 | $3.39M | Sell |
13,017
-120
| -0.9% | -$35.6K | 1.75% | 15 |
|
|
2024
Q3 | $4.23M | Sell |
13,137
-650
| -5% | -$213K | 2.09% | 13 |
|
|
2024
Q2 | $4.31M | Buy |
13,787
+160
| +1% | +$47K | 2.15% | 13 |
|
|
2024
Q1 | $3.87M | Sell |
13,627
-115
| -0.8% | -$33.6K | 2.2% | 13 |
|
|
2023
Q4 | $3.96M | Sell |
13,742
-703
| -5% | -$192K | 2.1% | 13 |
|
|
2023
Q3 | $3.88M | Sell |
14,445
-155
| -1% | -$38.7K | 2% | 14 |
|
|
2023
Q2 | $3.24M | Buy |
14,600
+120
| +0.8% | +$27.8K | 1.6% | 17 |
|
|
2023
Q1 | $3.5M | Sell |
14,480
-125
| -0.9% | -$30.7K | 1.7% | 16 |
|
|
2022
Q4 | $3.84M | Sell |
14,605
-598
| -4% | -$160K | 1.92% | 15 |
|
|
2022
Q3 | $3.43M | Sell |
15,203
-1,548
| -9% | -$375K | 2.11% | 13 |
|
|
2022
Q2 | $4.08M | Sell |
16,751
-265
| -2% | -$64.9K | 2.09% | 13 |
|
|
2022
Q1 | $4.12M | Sell |
17,016
-395
| -2% | -$90.8K | 1.81% | 15 |
|
|
2021
Q4 | $3.92M | Sell |
17,411
-606
| -3% | -$128K | 1.7% | 16 |
|
|
2021
Q3 | $3.83M | Sell |
18,017
-245
| -1% | -$56.4K | 1.74% | 18 |
|
|
2021
Q2 | $4.45M | Buy |
18,262
+732
| +4% | +$180K | 2.05% | 15 |
|
|
2021
Q1 | $4.36M | Sell |
17,530
-766
| -4% | -$183K | 2.16% | 15 |
|
|
2020
Q4 | $4.21M | Buy |
18,296
+482
| +3% | +$111K | 2.17% | 14 |
|
|
2020
Q3 | $4.53M | Sell |
17,814
-1,240
| -7% | -$307K | 2.68% | 12 |
|
|
2020
Q2 | $4.49M | Buy |
19,054
+104
| +0.5% | +$23.7K | 2.77% | 12 |
|
|
2020
Q1 | $3.84M | Buy |
18,950
+190
| +1% | +$41.5K | 3.01% | 12 |
|
|
2019
Q4 | $4.52M | Sell |
18,760
-985
| -5% | -$217K | 2.75% | 12 |
|
|
2019
Q3 | $3.82M | Sell |
19,745
-2,019
| -9% | -$388K | 2.3% | 14 |
|
|
2019
Q2 | $4.01M | Sell |
21,764
-200
| -0.9% | -$35.8K | 2.15% | 15 |
|
|
2019
Q1 | $4.17M | Sell |
21,964
-459
| -2% | -$87.7K | 2.25% | 14 |
|
|
2018
Q4 | $4.37M | Buy |
22,423
+60
| +0.3% | +$11.7K | 2.65% | 11 |
|
|
2018
Q3 | $4.64M | Buy |
22,363
+1,819
| +9% | +$358K | 2.42% | 13 |
|
|
2018
Q2 | $3.79M | Sell |
20,544
-1,917
| -9% | -$339K | 2.26% | 13 |
|
|
2018
Q1 | $3.83M | Buy |
22,461
+70
| +0.3% | +$12.8K | 2.46% | 13 |
|
|
2017
Q4 | $3.89M | Sell |
22,391
-4,650
| -17% | -$823K | 2.08% | 16 |
|
|
2017
Q3 | $5.04M | Sell |
27,041
-282
| -1% | -$50K | 2.53% | 13 |
|
|
2017
Q2 | $4.71M | Sell |
27,323
-750
| -3% | -$122K | 2.45% | 14 |
|
|
2017
Q1 | $4.61M | Buy |
28,073
+461
| +2% | +$76.6K | 2.37% | 16 |
|
|
2016
Q4 | $4.04M | Sell |
27,612
-1,740
| -6% | -$262K | 2.12% | 18 |
|
|
2016
Q3 | $4.9M | Buy |
29,352
+870
| +3% | +$147K | 2.51% | 15 |
|
|
2016
Q2 | $4.33M | Sell |
28,482
-3,280
| -10% | -$510K | 1.96% | 20 |
|
|
2016
Q1 | $4.76M | Buy |
31,762
+465
| +1% | +$69.1K | 1.53% | 29 |
|
|
2015
Q4 | $5.08M | Buy |
31,297
+25,250
| +418% | +$3.97M | 1.53% | 26 |
|
|
2015
Q3 | $836K | Sell |
6,047
-2,367
| -28% | -$373K | 0.2% | 63 |
|
|
2015
Q2 | $1.29M | Buy |
8,414
+3,000
| +55% | +$481K | 0.29% | 54 |
|
|
2015
Q1 | $865K | Hold |
5,414
| – | – | 0.19% | 61 |
|
|
2014
Q4 | $862K | Hold |
5,414
| – | – | 0.18% | 61 |
|
|
2014
Q3 | $760K | Hold |
5,414
| – | – | 0.15% | 69 |
|
|
2014
Q2 | $641K | Sell |
5,414
-200
| -4% | -$23.2K | 0.13% | 74 |
|
|
2014
Q1 | $692K | Buy |
5,614
+200
| +4% | +$24.3K | 0.14% | 69 |
|
|
2013
Q4 | $618K | Buy |
5,414
+2,000
| +59% | +$228K | 0.15% | 63 |
|
|
2013
Q3 | $382K | Sell |
3,414
-500
| -13% | -$54.2K | 0.08% | 84 |
|
|
2013
Q2 | $386K | Buy |
+3,914
| New | +$406K | 0.1% | 71 |
|
Other funds holding AMGN
VCM
VPM
Chelsea Counsel Company's AMGN Position: Q1 2026 in Review
Chelsea Counsel Company reduced its Amgen (AMGN) stake by 14% in Q1 2026, selling an estimated $535K and leaving 9,374 shares worth $3.3M. The position accounts for 1.47% of the portfolio, ranked #19.
Chelsea Counsel Company first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.08M in Q4 2015. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Chelsea Counsel Company held 9,374 shares of Amgen worth $3.3M as of Q1 2026.
- Chelsea Counsel Company sold 1,500 Amgen shares in Q1 2026, an estimated $535K.
- Amgen made up 1.47% of Chelsea Counsel Company's portfolio in Q1 2026, its #19 holding.
- Chelsea Counsel Company first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
- Chelsea Counsel Company's Amgen position peaked at $5.08M in Q4 2015.
- 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Chelsea Counsel Company's 13F filing for Q1 2026, filed 24 Apr 2026.